Neovacs S.A. (ALNEV) — Cash Flow-to-Debt Ratio
Neovacs S.A. (ALNEV) has a Cash Flow-to-Debt Ratio of -0.63x as of December 2025, meaning its operating cash flow of €-2.60 Million could theoretically repay -1% of its total liabilities (€4.10 Million) in one year. Check cash flow reinvestment rate of Neovacs S.A. to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Neovacs S.A. Cash Flow-to-Debt Ratio (2007–2025)
Historical debt coverage capacity for Neovacs S.A. across 19 annual periods. Check how high is Neovacs S.A.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.
Annual Cash Flow-to-Debt Ratio for Neovacs S.A. (2007–2025)
Year-by-year debt coverage analysis for Neovacs S.A.. For the full cash flow conversion analysis, see Neovacs S.A. cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.23x | €-5.03 Million | €4.10 Million | ▼ -36.6% |
| 2024 | -0.90x | €-3.60 Million | €4.01 Million | ▼ -74.3% |
| 2023 | -0.52x | €-1.91 Million | €3.71 Million | ▲ +41.5% |
| 2022 | -0.88x | €-4.45 Million | €5.05 Million | ▲ +58.7% |
| 2021 | -2.13x | €-9.91 Million | €4.65 Million | ▲ +5.6% |
| 2020 | -2.26x | €-5.65 Million | €2.50 Million | ▼ -33.7% |
| 2019 | -1.69x | €-8.10 Million | €4.80 Million | ▲ +39.1% |
| 2018 | -2.77x | €-13.31 Million | €4.80 Million | ▼ -110.4% |
| 2017 | -1.32x | €-14.26 Million | €10.82 Million | ▲ +3.2% |
| 2016 | -1.36x | €-11.00 Million | €8.08 Million | ▲ +8.2% |
| 2015 | -1.48x | €-7.69 Million | €5.18 Million | ▲ +35.7% |
| 2014 | -2.31x | €-8.05 Million | €3.49 Million | ▼ -38.1% |
| 2013 | -1.67x | €-7.00 Million | €4.19 Million | ▲ +31.6% |
| 2012 | -2.44x | €-6.33 Million | €2.59 Million | ▲ +31.6% |
| 2011 | -3.57x | €-8.63 Million | €2.41 Million | ▼ -6.1% |
| 2010 | -3.37x | €-8.10 Million | €2.40 Million | ▼ -106.6% |
| 2009 | -1.63x | €-7.95 Million | €4.88 Million | ▲ +20.4% |
| 2008 | -2.05x | €-4.49 Million | €2.19 Million | ▲ +3.5% |
| 2007 | -2.12x | €-4.32 Million | €2.04 Million | — |